Email
Password
Remember meForgot password?
Log in with Facebook Log in with Twitter
Connect your Digital Journal account with Facebook or Twitter to use this feature.
Press Release

Drugs for Treating Systemic Lupus Erythematosus: Global Markets

PR Newswire

NEW YORK, April 8, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Drugs for Treating Systemic Lupus Erythematosus: Global Markets
http://www.reportlinker.com/p02070064/Drugs-for-Treating-Systemic-Lupus-Erythematosus-Global-Markets.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

REPORT HIGHLIGHTS

The global market for drugs to treat systemic lupus erythematosus (SLE) is expected to reach $950.2 million in 2013 and $2.6 billion in 2018, a compound annual growth rate (CAGR) of 22.4%.

This report provides:


An overview of the global market for drugs and therapeutics used to treat systemic lupus erythematosus (SLE)
Analyses of global market trends, with data from 2013 and projections of CAGRs through 2018.
Analyses of factors influencing market demand such as the industry's structure, governmental regulations, and developing technologies
Details concerning the developmental product pipeline for therapeutics uesd to treat SLE
Profiles of leading companies in the industry.

STUDY GOALS AND OBJECTIVES

BCC Research's goal in conducting this study was to determine the current status of systemic lupus erythematosus (SLE) disease treatments and assess the growth potential of this area over a five-year period, from 2013 to 2018. Our key objective was to present a comprehensive analysis of the current pipeline of therapeutics, analyze the market and forecast for SLE therapeutics along with outlining the key factors that will influence this therapeutic area in the next few years.

REASONS FOR DOING THIS STUDY

SLE is a devastating and chronic autoimmune disorder affecting almost all the organs, with only one approved marketed drug — making this a significant area of unmet medical need. But there are now numerous companies developing novel treatments. This report will review the programs in development and quantify the market opportunities in SLE drugs.

SCOPE OF REPORT

The scope of this report focuses on the pharmaceutical segment. We have compiled a study of the market, as well as current and emerging modes of treatment. We present the market segment's economic environment, market factors and potential, and forecasts for 2013 to 2018. This study will be of interest to the drug industry, patients and the medical community. It will also be of interest to suppliers of products and services to this market area.

INTENDED AUDIENCE

The intended audience for this report is the pharmaceutical and biotechnology industries and diagnostics sector, as well as the medical practitioners who treat patients in these areas.
Chapter- 1: INTRODUCTION 2

STUDY GOALS AND OBJECTIVES
REASONS FOR DOING THIS STUDY
SCOPE OF REPORT
INTENDED AUDIENCE
METHODOLOGY
INFORMATION SOURCES
ANALYST'S CREDENTIALS
RELATED BCC RESEARCH REPORTS
BCC RESEARCH ONLINE SERVICES
DISCLAIMER

Chapter- 2: EXECUTIVE SUMMARY 8

KEY FACTORS DRIVING THE MARKET
KEY FACTORS RESTRICTING THE MARKET
NOTABLE PIPELINE ACTIVITIES
KEY CHALLENGES IN THE MARKET FOR SLE THERAPIES
KEY OPPORTUNITIES IN THE MARKET FOR SLE THERAPIES
Table 0 A : GLOBAL SALES OF DRUGS TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, BY REGION, THROUGH 2018
Figure 0 A : GLOBAL SALES OF DRUGS TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, BY REGION, 2012-2018
Table 0 B : GLOBAL SALES OF DRUG CLASSES USED TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, THROUGH 2018
Figure 0 B : GLOBAL SLE MARKET-SHARE OF DRUG CLASSES USED TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, 2012-2018

Chapter- 3: OVERVIEW

SIGNS AND SYMPTOMS
TYPES OF LUPUS
PATHOPHYSIOLOGY
PROGRESSION AND SEVERITY
ETIOLOGY
EPIDEMIOLOGY AND PATIENT POPULATIONS
DIAGNOSED AND DRUG TREATED POPULATION

Chapter- 4: CURRENT MEDICAL PRACTICE AND MARKET PROFILES 16 $1237

DIAGNOSIS SCREENING AND PUBLIC AWARENESS
CLINICAL RECOMMENDATIONS AND DIAGNOSIS ALGORITHM
REFERRAL PATTERNS

Chapter- 5: CURRENT THERAPIES

ANTIMALARIAL DRUGS
NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS)
CORTICOSTEROIDS
CYTOTOXIC AND IMMUNOSUPPRESSIVE DRUGS
BIOLOGICS
BIOLOGICS APPROVED FOR TREATING SLE
BIOLOGICS USED OFF-LABEL
SMALL MOLECULES
Table 8 : CURRENT DRUGS USED IN THE TREATMENT FOR SYSTEMIC LUPUS ERYTHEMATOSUS AND THEIR MECHANISM

Chapter- 6: UNMET NEEDS

EFFICACY AND SAFETY
NEED FOR PREVENTION OF ATHEROSCLEROSIS
STEROID SPARING THERAPY TO REDUCE THE DOSE AND DURATION OF STEROID USE
THERAPIES TAILORED TO INDIVIDUAL PATIENTS
PREVENTION OF NEUROCOGNITIVE DYSFUNCTION
PREVENTION OF OSTEOPOROSIS AND OSTEONECROSIS
EARLY DIAGNOSIS

Chapter- 7: EMERGING THERAPIES

DRUG DEVELOPMENT AND REGULATORY CHALLENGES
EMERGING THERAPIES
B-CELL MODULATORS
T-CELL MODULATORS
IMMUNOSUPPRESSIVE AND CYTOTOXIC DRUGS
PROINFLAMMATORY AND CYTOKINE INHIBITORS

Chapter- 8: MARKET OUTLOOK 18 $1392

UNITED STATES
FRANCE
GERMANY
U.K.
SPAIN
ITALY
JAPAN
Table 17 : GLOBAL SALES OF DRUGS TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, 2012-2018
Table 18 : GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET -SALES IN MAJOR MARKETS, THROUGH 2018
Table 19 : GLOBAL SALES OF DRUG CLASSES USED TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, THROUGH 2018
Figure 5 : GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET-VALUE OF DRUG CLASSES, 2013 AND 2018

Chapter- 9: PATENTS

Table 35 : NO. OF PATENTS
Table 36 : ISSUED PATENTS
Table 37 : PATENT APPLICATIONS

Chapter- 10: COMPANY PROFILES

ANTHERA PHARMACEUTICALS INC
BIOTEST AG
BIOTICA TECHNOLOGY LTD.
CEPHALON
CORNERSTONE THERAPEUTICS INC.
CREABILIS THERAPEUTICS S.R.L.
DYNAVAX TECHNOLOGIES
ELI LILLY
F. HOFFMANN-LA ROCHE LTD
GLAXOSMITHKLINE PLC (GSK)
HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT

HANSA MEDICAL AB
HARBOR BIOSCIENCES
IMMUNOMEDICS, INC.
IDERA PHARMACEUTICALS INC.
IMMUPHARMA PLC
JOHNSON & JOHNSON LTD.
ISOTECHNIKA PHARMA INC
KINETA INC.
KYORIN PHARMACEUTICALS CO. LTD
LYCERA CORPORATION
MERCK KGAA
MACROGENICS, INC.
NOVO NORDISK
NEOVACS S.A.
NASVAX LTD.
ONYX PHARMACEUTICALS INC.
PHARMACYCLIS
PORTOLA PHARMACEUTICALS INC.
PFIZER LIMITED
REVO BIOLOGICS
RIGEL PHARMACEUTICALS INC
SANOFI
TEVA PHARMACEUTICAL INDUSTRIES LTD.
UCB GROUP/ IMMUNOMEDICS
VACCINEX INC.

List of Tables

Summary Table C : SUMMARY OF KEY PARAMETERS OF SYSTEMIC LUPUS ERYTHEMATOSUS MARKET, THROUGH 2018
Summary Table B : GLOBAL SALES OF DRUG CLASSES USED TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, THROUGH 2018
Summary Table A : GLOBAL SALES OF DRUGS TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, BY REGION, THROUGH 2018
Table 1 : PERCENTAGE OF PATIENTS WITH DIFFERENT CLINICAL MANIFESTATIONS OF SLE DISEASE
Table 2 : DESCRIPTION OF DIFFERENT TYPES OF SLE DISEASE MANIFESTATIONS
Table 3 : Classification of Lupus Nephritis
Table 4 : WORLD HEALTH ORGANIZATION CLASSIFICATION OF LUPUS NEPHRITIS
Table 5 : DIAGNOSED PREVALENCE AND DRUG TREATED SLE PATIENT POPULATION
Table 6 : DIAGNOSIS OF SYSTEMIC LUPUS ERYTHEMATOSUS BASED ON MANIFESTATIONS
Table 7 : TREATMENT ALGORITHM OF SYSTEMIC LUPUS ERYTHEMATOSUS
Table 8 : CURRENT DRUGS USED IN THE TREATMENT FOR SYSTEMIC LUPUS ERYTHEMATOSUS AND THEIR MECHANISM
Table 9 : BELIMUMAB EFFICACY DATA (BLISS-52: PRIMARY ENDPOINT AND COMPONENTS OF SLE RESPONDER INDEX)
Table 10 : ENDPOINTS USED IN CLINICAL TRIALS FOR SLE

Table 11 : CURRENT THERAPIES FOR SYSTEMIC LUPUS ERYTHEMATOSUS, TREATMENT BY DAILY DOSE AND THE MANIFESTATION TARGETED
Table 12 : TREATMENT FOR SYSTEMIC LUPUS ERYTHEMATOSUS BASED ON ORGAN INVOLVEMENT AND DISEASE SEVERITY
Table 13 : STEROIDS USED FOR TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS ACROSS DIFFERENT DISEASE SEVERITY
Table 14 : EMERGING THERAPIES BY PHASES OF DEVELOPMENT
Table 15 : NUMBER OF PROGRAMS AT EACH CLINICAL PHASES OF CLINICAL DEVELOPMENT
Table 16 : POSITIONING OF LEADING EMERGING THERAPIES FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS IN THE FUTURE
Table 17 : GLOBAL SALES OF DRUGS TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, 2012-2018
Table 18 : GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET -SALES IN MAJOR MARKETS, THROUGH 2018
Table 19 : GLOBAL SALES OF DRUG CLASSES USED TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, THROUGH 2018
Table 20 : U.S. — SALES OF DRUG CLASSES USED TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, 2012–2018
Table 21 : FRANCE: SALES OF DRUG CLASSES USED TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, THROUGH 2018
Table 22 : GERMANY: SALES OF DRUG CLASSES USED TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, THROUGH 2018
Table 23 : U.K.: SALES OF DRUG CLASSES USED TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, THROUGH 2018

Table 24 : SPAIN: SALES OF DRUG CLASSES USED TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, THROUGH 2018
Table 25 : ITALY: SALES OF DRUG CLASSES USED TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, THROUGH 2018
Table 26 : JAPAN: SALES OF DRUG CLASSES USED TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, THROUGH 2018
Table 27 : SALES OF BIOLOGICS AND SMALL MOLECULE DRUGS TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, THROUGH 2018
Table 28 : SALES OF DRUGS TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS IN THE MAJOR PHARMACEUTICAL MARKET OF THE U.S., THROUGH 2018
Table 29 : SALES OF DRUGS TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS IN THE MAJOR PHARMACEUTICAL MARKET OF FRANCE, THROUGH 2018
Table 30 : SALES OF DRUGS TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS IN THE MAJOR PHARMACEUTICAL MARKET OF GERMANY,THROUGH 2018
Table 31 : SALES OF DRUGS TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS IN THE MAJOR PHARMACEUTICAL MARKET OF THE U.K., THROUGH 2018
Table 32 : SALES OF DRUGS TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS IN THE MAJOR PHARMACEUTICAL MARKET OF SPAIN, THROUGH 2018
Table 33 : SALES OF DRUGS TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS IN THE MAJOR PHARMACEUTICAL MARKET OF ITALY, THROUGH 2018
Table 34 : SALES OF DRUGS TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS IN THE MAJOR PHARMACEUTICAL MARKET OF JAPAN, THROUGH 2018
Table 35 : NO. OF PATENTS
Table 36 : ISSUED PATENTS
Table 37 : PATENT APPLICATIONS

List of Figures

Figure 1 : DIAGNOSIS OF SYSTEMIC LUPUS ERYTHEMATOSUS
Figure 2 : PATIENT CARE PATH IN SYSTEMIC LUPUS ERYTHEMATOSUS
Figure 3 : TREATMENT DECISION TREE FOR SYSTEMIC LUPUS ERYTHEMATOSUS
Figure 4 : NUMBER OF PROGRAMS AT EACH CLINICAL PHASE
Figure 5 : GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET-VALUE OF DRUG CLASSES, 2013 AND 2018
Figure 6 : U.S. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET-VALUE OF DRUG CLASSES, 2013 AND 2018
Figure 7 : FRANCE: SYSTEMIC LUPUS ERYTHEMATOSUS MARKET-VALUE OF DRUG CLASSES, 2013 AND 2018
Figure 8 : GERMANY: SYSTEMIC LUPUS ERYTHEMATOSUS MARKET-VALUE OF DRUG CLASSES, 2013 AND 2018
Figure 9 : U.K: SYSTEMIC LUPUS ERYTHEMATOSUS MARKET-VALUE OF DRUG CLASSES, 2013 AND 2018
Figure 10 : SPAIN: SYSTEMIC LUPUS ERYTHEMATOSUS MARKET-VALUE OF DRUG CLASSES, 2013 AND 2018
Figure 11 : ITALY: SYSTEMIC LUPUS ERYTHEMATOSUS MARKET-VALUE OF DRUG CLASSES, 2013 AND 2018
Figure 12 : JAPAN: SYSTEMIC LUPUS ERYTHEMATOSUS MARKET 2013-2018-VALUE OF DRUG CLASSES, 2013 AND 2018

To order this report: Drugs for Treating Systemic Lupus Erythematosus: Global Markets
http://www.reportlinker.com/p02070064/Drugs-for-Treating-Systemic-Lupus-Erythematosus-Global-Markets.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker

Latest News
Top News

Corporate

Help & Support

News Links

copyright © 2014 digitaljournal.com   |   powered by dell servers